进行性多灶性白质脑病治疗进展  

Advances in the treatment of progressive multifocal leukoencephalopathy

作　　者：李骜航 杜小莉[1] LI Aohang;DU Xiaoli(Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院药剂科,北京100730

出　　处：《临床药物治疗杂志》2025年第2期1-4,共4页Clinical Medication Journal

摘　　要：进行性多灶性白质脑病(PML)是一种由JC病毒感染引起的中枢神经系统脱髓鞘疾病,通常在免疫系统受损的患者中多发。目前缺乏针对JC病毒的特效药物,对于HIV引起的PML,高效抗逆转录病毒治疗具有较好的疗效;对于由免疫抑制剂引起的PML,应立即停止使用免疫抑制剂。新兴的免疫检查点抑制剂在某些PML中显示出潜在的治疗效果。未来研究需进一步探索针对JC病毒的特异性疗法,优化个体化治疗方案,以改善患者预后。Progressive multifocal leukoencephalopathy(PML)is a demyelinating disease of the central nervous system caused by John Cunningham virus(JCV)infection,predominantly occurring in immunocompromised individuals.Currently,there are no specific antiviral drugs targeting JCV.Highly active anti-retroviral therapy has demonstrated efficacy in managing HIV-related PML,while for PML caused by immunosuppressants,immediate discontinuation of the immunosuppressive agent is essential.Emerging immune checkpoint inhibitors have shown potential therapeutic benefits in certain cases.Further research should focus on developing JCV-specific antiviral therapies and optimizing individualized treatment approaches to improve patient outcomes and prognosis.

关 键 词：进行性多灶性白质脑病 JC病毒 免疫抑制剂 高效抗逆转录病毒治疗 

分 类 号：R971[医药卫生—药品] R744.5[医药卫生—药学]